The global smart pills market is a rapidly growing sector within the healthcare industry. Smart pills, equipped with sensors and wireless technology, offer real-time monitoring, diagnosis, and targeted drug delivery. They improve patient compliance, enable personalized medicine, and facilitate remote patient monitoring. With technological advancements and the increasing prevalence of chronic diseases, the market is driven by factors such as improved healthcare outcomes, cost-effectiveness, and the demand for non-invasive healthcare solutions.
Get Free Sample Report: https://databridgemarketresearch.com/reports/global-smart-pills-market
Data Bridge Market Research analyses that the Smart Pills Market is expected to grow at a value of USD 14.42 billion by 2029, with a CAGR of around 16.71% during the forecast period from 2022 to 2029 from USD 4.19 billion in 2021. Smart pills allow for real-time monitoring of the gastrointestinal tract and provide valuable data to healthcare providers. This enables remote patient care, as healthcare professionals can review the captured images and data to make accurate diagnoses and treatment decisions. The increasing demand for remote monitoring and telemedicine services is driving the adoption of smart pills.
Key Findings of the Study
Focus on personalized medicine is expected to drive the market's growth rate
Smart pills play a crucial role in enabling personalized medicine by providing real-time data on patient medication response. This data helps healthcare providers tailor treatment plans and optimize therapy based on individual patient needs. Monitoring factors such as drug absorption, adherence, and physiological response, smart pills enable adjustments in dosages and treatment regimens. This personalized approach improves treatment effectiveness, minimizes side effects, and enhances patient outcomes, ultimately leading to more precise and targeted healthcare interventions.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2022 to 2029
|
Base Year
|
2021
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Type (Multi parameter Monitoring, Single Parameter Monitoring), Disease Indication (Occult GI Bleeding, Crohn’s Disease, Small Bowel Tumors, Celiac Disease, Inherited Polyposis Syndromes, Mental Disorders), Application (Capsule Endoscopy, Drug Delivery, Patient Monitoring of Cancer), End User (Hospital, Diagnostic Centers, Others)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
Market Players Covered
|
ACAMP (Canada), BDD Ltd (South Korea), Boston Scientific Corporation (U.S.),Cerner Corporation (U.S.),FUJIFILM Holdings Corporation (Japan), GENERAL ELECTRIC COMPANY (U.S.), MEDTRONIC (Ireland), Olympus Corporation (Japan), PENTAX Medical (Japan), Proteus Digital Health (U.S.) among others
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The smart pills market is segmented on the basis of type, disease indication, application, and end user
- On the basis of type, the smart pills market is segmented into multi parameter monitoring and single parameter monitoring. Multipara meter monitoring segment dominates due to its ability to measure multiple parameters simultaneously, providing comprehensive and real-time data for various applications. This allows for a more comprehensive understanding of the monitored system compared to single parameter monitoring in the forecast period of 2022-2029.
- On the basis of disease indication, the smart pills market is segmented into occult GI bleeding, Crohn’s disease, small bowel tumors, celiac disease, inherited polyposis syndromes and mental disorders. Occult GI bleeding holds dominance in disease indication due to its significance as a hidden source of gastrointestinal bleeding that requires accurate diagnosis and monitoring. Capsule endoscopy is commonly used to detect and evaluate occult GI bleeding, contributing to its dominance in the forecast period of 2022-2029.
- On the basis of application, the smart pills market is segmented into capsule endoscopy, drug delivery, and patient monitoring of cancer. The capsule endoscopy segment dominates the application segment of the market due to its non-invasive nature and ability to provide comprehensive visualization of the gastrointestinal tract, aiding in the diagnosis and monitoring of various digestive disorders and diseases in the forecast period of 2022-2029.
In 2022, the capsule endoscopy segment dominates the application segment of the market
2022 年，膠囊內視鏡憑藉其非侵入性、捕捉胃腸道詳細影像的能力以及在 2022-2029 年預測期內廣泛用於診斷胃腸道疾病的能力，將在市場應用領域佔據主導地位。
- 根據最終用戶，智慧藥丸市場分為醫院、診斷中心和其他。醫院部門在市場最終用戶部門中佔據主導地位，因為它們在提供醫療保健方面發揮著主要作用，並在 2022 年至 2029 年的預測期內廣泛使用尖端診斷工具進行患者護理和監測。
2022 年，醫院部門將主導市場的最終用戶部分
2022 年，醫院部門將主導市場的最終用戶部門，因為它們是初級醫療保健提供者，並且在 2022 年至 2029 年的預測期內廣泛使用先進的診斷技術進行患者護理和監測。
主要參與者
Data Bridge Market Research 認為以下公司是智慧藥丸 市場的主要參與者，它們是 Cerner Corporation（美國）、富士軟片控股公司（日本）、通用電氣公司（美國）、美敦力公司（愛爾蘭）、奧林巴斯公司（日本）、賓得醫療公司（日本）
市場開發
- 2023年，美國AnX Robotica Corp.在該國推出了NaviCam小腸系統。 NaviCam SB 系統利用非球面鏡片技術來改善視野並減少失真，這對於小腸疾病的診斷至關重要。
- 2021 年，PillCam Small Bowel 3 系統已獲得美國 FDA 的 510(k) 批准，可用於遠端內視鏡檢查程序。
- 2021年，Check-Cap（以色列）從單一來源供應商改善了技術問題，同時也提高了C-Scan的製造能力和現場生產線。為了支持其在美國的關鍵研究，該公司大幅擴展了其生產線。
- 2020 年，FDA 授予 AnX Robotica Corp.（美國）的 NaviCam 磁控膠囊內視鏡 (MCCE) 系統 De-Novo 分類。這是一個突破性的系統，它使用一個裝有攝影機的藥丸大小的膠囊來實現胃部的全面、即時可視化，並由醫生使用先進的磁性技術進行遠端控制。
- 2020年，美國CapsoVision公司獲得國際標準化組織（ISO）27001安全認證。該認證涵蓋 CapsoVision 的公司辦公室及其 CapsoCloud 軟體。此次認證證明了該公司長期致力於保護客戶資料。
區域分析
從地理上看，智慧藥丸市場報告涵蓋的國家有：北美洲的美國、加拿大和墨西哥，歐洲的德國、法國、英國、荷蘭、瑞士、比利時、俄羅斯、義大利、西班牙、土耳其，歐洲其他地區，中國、日本、印度、韓國、新加坡、馬來西亞、澳洲、泰國、印尼、菲律賓，亞太地區（APAC）的其他地區，沙烏地阿拉伯、阿拉伯聯合大公國、南非、埃及、印尼、菲律賓，亞太地區（APAC）的其他地區，沙烏地阿拉伯、阿聯酋、南非、埃及、以色列和其他
根據 Data Bridge 市場研究分析：
2022 年至 2029 年預測期內，北美是智慧藥丸市場的主導地區
北美在智慧藥丸市場的主導地位可歸因於其醫療保健領域的先進技術發展。該地區在智慧藥丸技術的開發和應用方面取得了重大進展。此外，結腸直腸癌發生率的上升和新型智慧藥丸產品的監管批准也促進了市場的成長。這些因素為預測期內北美智慧藥丸市場的擴張創造了有利的環境。
預計2022 年至 2029 年預測期內，亞太地區將成為智慧藥丸市場成長最快的地區
由於多個國家實施強制醫療保險，預計亞太地區的智慧藥丸市場將大幅成長。隨著醫療保險覆蓋範圍的擴大，越來越多的人能夠獲得醫療服務和治療，包括智慧藥丸。醫療資源和保險覆蓋範圍的擴大推動了對智慧藥丸等創新醫療技術的需求，從而導致亞太地區的市場顯著成長。
有關智能藥丸市場 報告的更多詳細信息，請單擊此處 - https://www.databridgemarketresearch.com/reports/global-smart-pills-market
